NRx Pharmaceuticals

NRx Pharmaceuticals to Spotlight Ketamine’s Potential and Risks in Keynote Address at Sachs Neuroscience Innovation Forum

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced that it will present a keynote address at the highly anticipated Sachs Neuroscience Innovation Forum in San Francisco later today.

NRx Pharmaceuticals to Spotlight Ketamine’s Potential and Risks in Keynote Address at Sachs Neuroscience Innovation Forum Read More

CSL Behring

CSL Behring Introduces Larger Vial Sizes for ZEMAIRA, Streamlining Treatment for the Alpha-1 Community

KING OF PRUSSIA, PA — CSL Behring has announced a significant development aimed at improving the treatment experience for patients with Alpha-1 antitrypsin deficiency. The Pennsylvania-based company has introduced 4- …

CSL Behring Introduces Larger Vial Sizes for ZEMAIRA, Streamlining Treatment for the Alpha-1 Community Read More